2019年冠状病毒病(COVID-19)
严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)
病毒学
抗体
受体
单克隆抗体
2019-20冠状病毒爆发
计算生物学
表位
生物
免疫学
医学
疾病
传染病(医学专业)
遗传学
爆发
病理
作者
Andrew C. Hunt,James Brett Case,Young‐Jun Park,Longxing Cao,Kejia Wu,Alexandra C. Walls,Zhuoming Liu,John E. Bowen,Andy Hsien-Wei Yeh,Shally Saini,Louisa Helms,Yan Ting Zhao,Tien-Ying Hsiang,Tyler N. Starr,Inna Goreshnik,Lisa Kozodoy,Lauren P. Carter,Rashmi Ravichandran,Lydia B. Green,Wadim L. Matochko
标识
DOI:10.1126/scitranslmed.abn1252
摘要
New variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue to arise and prolong the coronavirus disease 2019 (COVID-19) pandemic. Here, we used a cell-free expression workflow to rapidly screen and optimize constructs containing multiple computationally designed miniprotein inhibitors of SARS-CoV-2. We found the broadest efficacy was achieved with a homotrimeric version of the 75-residue angiotensin-converting enzyme 2 (ACE2) mimic AHB2 (TRI2-2) designed to geometrically match the trimeric spike architecture. Consistent with the design model, in the cryo-electron microscopy structure TRI2-2 forms a tripod at the apex of the spike protein that engaged all three receptor binding domains simultaneously. TRI2-2 neutralized Omicron (B.1.1.529), Delta (B.1.617.2), and all other variants tested with greater potency than the monoclonal antibodies used clinically for the treatment of COVID-19. TRI2-2 also conferred prophylactic and therapeutic protection against SARS-CoV-2 challenge when administered intranasally in mice. Designed miniprotein receptor mimics geometrically arrayed to match pathogen receptor binding sites could be a widely applicable antiviral therapeutic strategy with advantages over antibodies in greater resistance to viral escape and antigenic drift, and advantages over native receptor traps in lower chances of autoimmune responses.
科研通智能强力驱动
Strongly Powered by AbleSci AI